The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | BRUIN study cohort update: pirtobrutinib for patients with MCL
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the updated results from the Phase I/II BRUIN study (NCT03740529) investigating the oral agent pirtobrutinib for relapsed/refractory mantle cell lymphoma (R/R MCL), highlighting the response rates observed in both BTK inhibitor-naïve and -exposed patients. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
